1. Home
  2. ENVX vs EYPT Comparison

ENVX vs EYPT Comparison

Compare ENVX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovix Corporation

ENVX

Enovix Corporation

HOLD

Current Price

$4.88

Market Cap

1.3B

Sector

Miscellaneous

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$15.66

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVX
EYPT
Founded
2006
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Laboratory Analytical Instruments
Sector
Miscellaneous
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
ENVX
EYPT
Price
$4.88
$15.66
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$14.56
$31.00
AVG Volume (30 Days)
5.5M
1.7M
Earning Date
05-21-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
40.94
N/A
EPS
N/A
N/A
Revenue
$31,821,000.00
$7,539,000.00
Revenue This Year
$40.85
N/A
Revenue Next Year
$236.84
$965.51
P/E Ratio
N/A
N/A
Revenue Growth
37.91
N/A
52 Week Low
$4.84
$3.91
52 Week High
$16.49
$19.11

Technical Indicators

Market Signals
Indicator
ENVX
EYPT
Relative Strength Index (RSI) 30.07 48.07
Support Level N/A $11.88
Resistance Level $8.73 $19.06
Average True Range (ATR) 0.37 1.43
MACD -0.05 0.07
Stochastic Oscillator 0.94 50.31

Price Performance

Historical Comparison
ENVX
EYPT

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: